-->

Company Registry

Zalgen Labs LLC
Profile last edited on: 11/15/2018

Immunotherapeutics, novel vaccines, and reliable, rapid, and affordable diagnostic platforms
Year Founded
2011
First SBIR Year
2010
Latest SBIR Award
2019
Program Status
Active

WikiProfile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

20271 Goldenrod Lane Suite 2083
Germantown, MD 20876
   (504) 444-7047
   admin@zalgenlabs.com
   www.zalgenlabs.com
Multiple Locations:   
Congressional District:   06
County:   Montgomery

Public Profile

Zalgen has core competency in the development of platforms for generation of high quality recombinant proteins from difficult-to-express genes. The firm's approaches are supported by the development of first-to-field-use rapid diagnostic tests for Lassa hemorrhagic fever (LHF) by a consortium of academic, institutional, and biotechnology entities, led by one of Zalgens' founders, These diagnostics are changing the understanding of epidemiological, immunological, and basic research notions in LHF, contributing toimprovements in the management and successful outcome of this viral disease. Principals of the firm have developed effective methods for production of Lassa virus-like particles (VLP), which are empty and non-infectious virions containing all the immunologically relevant viral proteins in quasi-native conformation. Lassa VLP are being tested as possible next generation vaccine platforms for LHF, and have shown efficacy in preliminary in vivo studies. This VLP technology has broad applications in vaccine and diagnostic platform development for a wide array of enveloped viruses. These two programs are factors in the development of first-in-class immunotherapeutics for prophylaxis and treatment of LHF. he first three fully human monoclonal antibodies, administered in single or cocktail formats have demonstrated remarkable efficacy in relevant animal models in Biosafety Level-4 (BSL-4) settings. Zalgen

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
15-19
Revenue Range
1.5M-2M
VC funded?
No
Public/Private
Privately Held
Stock Info
---
IP Holdings
N/A

Awards Distribution by Agency

Key People / Management

  Luis Manuel Branco -- President & Co-Founder

  Matthew L Boisen --

  Robert F Garry -- Co-Founder

SBIR firms in the news

There are no news available.